SWK HOLDINGS CORP. overview

DALLAS, TX / ACCESS Newswire / March 19, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the monetization of its royalty portfolio through two transactions. On March 17, 2025, ANI Pharmaceuticals, Inc. exercised its buyout option related to the Iluvien royalty, which resulted in a payment of approximately $17.3 million to SWK. In a separate...

Conference Call Scheduled for Thursday, March 20, 2025, at 09:00 a.m. CST Corporate Highlights Fourth quarter 2024 GAAP net income was $5.9 million, compared with GAAP net income of $2.8 million for the fourth quarter 2023. Fourth quarter 2024 finance receivables segment adjusted non-GAAP net income was $6.2 million, compared with adjusted non-GAAP net income of $3.7 million for the fourth quarter 2023. As of December 31, 2024, net finance receivables were $277.8 million, a 1.2% increase from...

DALLAS, TX / ACCESS Newswire / March 13, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that it will issue its fourth quarter and full year 2024 earnings results after the market close on Wednesday, March 19, 2025. The Company will host a conference call to discuss its corporate and financial results on Thursday, March 20, 2025 at 10:00am ET. The...

DALLAS, TX / ACCESSWIRE / January 6, 2025 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update for material events occurring since September 30, 2024. Originations In November, SWK advanced $5.0M to existing borrower Journey Medical to help fund the company's launch of Emrosi TM . In November, as part of a broader amendment SWK advanced...

Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CST Corporate Highlights Third quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023. Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023. As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from...

Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (Nasdaq:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule. The Company intends to issue their third quarter financials after market close on November 14,...

Conference Call Scheduled for Friday, August 16, 2024, at 09:00 a.m. CST Corporate Highlights Second quarter 2024 GAAP net income was $4.4 million, compared with net income of $3.9 million for the second quarter 2023 Second quarter 2024 finance receivables segment adjusted non-GAAP net income was $6.5 million, compared with adjusted non-GAAP net income of $7.6 million for the second quarter 2023 As of June 30, 2024, net finance receivables were $265.5 million, a 19.0% increase from June 30, 2023...